Quest Diagnostics Incorporated
Company History
Quest Diagnostics History: Founding, Growth & Key Milestones
Founded 1967 in New York City, New York, United States
When was Quest Diagnostics founded?
Quest Diagnostics was founded in 1967 in New York City, New York, United States by Dr. Paul A. Brown, making it 59 years old.
- Founded
- 1967
- Founding place
- New York City, New York, United States
- Founders
- Dr. Paul A. Brown
- Headquarters today
- Secaucus, New Jersey, United States
- Milestones documented
- 19 (1967–2026)
- Current CEO
- James Davis
- Acquisitions
- 8
| Year | Event |
|---|---|
| 1967 | Metropolitan Pathology Laboratory Founded by Dr. Paul A. Brown |
| 1982 | Corning Glass Works Acquires MetPath |
| 1996 | Spin-off from Corning as Independent Public Company |
| 1999 | Acquisition of SmithKline Beecham Clinical Laboratories |
| 2003 | Acquisition of Unilab Corporation for $800 Million |
| 2005 | Acquisition of LabOne, Inc. for $934 Million |
| 2007 | Acquisition of AmeriPath for Approximately $1.23 Billion |
| 2011 | Acquisitions of Athena Diagnostics and Celera Corporation |
| 2014 | Acquisition of Solstas Lab Partners Group for $570 Million |
| 2018 | Launch of QuestDirect Consumer-Initiated Testing |
| 2020 | COVID-19 Testing Launch and Pandemic Response |
| 2020 | Acquisition of Blueprint Genetics for $108 Million |
| 2022 | Jim Davis Becomes CEO, Succeeding Steve Rusckowski |
| 2023 | Acquisition of Haystack Oncology and NewYork-Presbyterian Outreach |
| 2024 | Acquisition of LifeLabs from OMERS for CAD $1.35 Billion |
| 2025 | Acquisition of Fresenius Medical Care Spectra Laboratories Assets |
| 2025 | Record Financial Performance and Raised 2026 Guidance |
| 2026 | Q1 2026 Results Raise Guidance |
| 2026 | Q2 2026 Results and Second Guidance Raise |
- Where was Quest Diagnostics founded?
- Quest Diagnostics was founded in New York City, New York, United States in 1967. wikidata.org
- Who founded Quest Diagnostics?
- Quest Diagnostics was founded by Dr. Paul A. Brown.
- When did Quest Diagnostics start?
- Quest Diagnostics was founded in 1967.
- How old is Quest Diagnostics?
- Quest Diagnostics is 59 years old as of 2026.
Founding Story
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory in 1967. He bet that centralized, high-volume testing could serve physicians faster and more cheaply than small local labs. The company was renamed MetPath in 1969. Corning Glass Works bought it in 1982, and it became Corning Clinical Laboratories. Corning spun off the business as Quest Diagnostics on December 31, 1996.
Founders
Dr. Paul A. Brown
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory in 1967, which was renamed MetPath in 1969. He built it around centralized, automated, high-volume testing for physicians' offices instead of small local labs. MetPath grew into one of the largest U.S. clinical labs before Corning Glass Works bought it in 1982. That business later became Quest Diagnostics. Dr. Paul A. Brown was born in 1938. Education: Harvard College; Tufts University School of Medicine; Tufts University. Brown was born on April 1, 1938 and died on January 7, 2024. He was a pathologist, academic and writer.
Key Milestones
Metropolitan Pathology Laboratory Founded by Dr. Paul A. Brown
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory, Inc. in Teaneck, New Jersey, to provide clinical laboratory services to local physicians and hospitals. The company was renamed MetPath, Inc. in 1969.
Source: en.wikipedia.orgCorning Glass Works Acquires MetPath
Corning Glass Works acquired MetPath and renamed it Corning Clinical Laboratories. This acquisition provided capital and corporate infrastructure for expansion but also meant the laboratory business was a small division within a larger materials science company.
Source: en.wikipedia.orgSpin-off from Corning as Independent Public Company
On December 31, 1996, Quest Diagnostics became an independent company through a spin-off from Corning and began trading on the NYSE under ticker DGX. Kenneth W. Freeman was appointed CEO. The spin-off provided strategic flexibility to pursue an acquisition-driven growth strategy.
Source: en.wikipedia.orgAcquisition of SmithKline Beecham Clinical Laboratories
Quest acquired SmithKline Beecham Clinical Laboratories for approximately $1.3 billion in cash and stock. SBCL had generated $1.6 billion in 1998 revenue and added a national network of laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size and established it as the industry leader.
Source: en.wikipedia.orgAcquisition of Unilab Corporation for $800 Million
Quest acquired Unilab Corporation for $800 million, significantly expanding its West Coast presence and adding substantial volume in California and surrounding states. The acquisition required divestiture of certain Northern California assets to LabCorp for antitrust clearance.
Source: en.wikipedia.orgAcquisition of LabOne, Inc. for $934 Million
Quest acquired LabOne, Inc. for $934 million, adding employer drug testing and paramedical testing capabilities that expanded the company's service offerings beyond traditional clinical laboratory testing.
Source: en.wikipedia.orgAcquisition of AmeriPath for Approximately $1.23 Billion
Quest acquired AmeriPath and its subsidiary Specialty Laboratories for approximately $1.23 billion, adding anatomic pathology and cancer diagnostic testing capabilities that complemented Quest's clinical chemistry strengths.
Source: en.wikipedia.orgAcquisitions of Athena Diagnostics and Celera Corporation
Quest acquired Athena Diagnostics (neurodegenerative disease testing) and Celera Corporation (genomics and sequencing), adding advanced diagnostics capabilities in neurology and genetic testing that would become foundational for future growth initiatives.
Source: en.wikipedia.orgAcquisition of Solstas Lab Partners Group for $570 Million
Quest acquired Solstas Lab Partners Group for $570 million, expanding its geographic footprint in the Southeastern United States and adding hospital outreach laboratory relationships.
Source: en.wikipedia.orgLaunch of QuestDirect Consumer-Initiated Testing
Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing without a physician order in states where permitted. This marked Quest's entry into the direct-to-consumer diagnostic market.
Source: en.wikipedia.orgCOVID-19 Testing Launch and Pandemic Response
Quest launched COVID-19 testing in March 2020 and by July 2020 had performed more than 9.2 million molecular tests and 2.8 million serology tests. The pandemic created both operational challenges and substantial revenue opportunities for the company.
Source: en.wikipedia.orgAcquisition of Blueprint Genetics for $108 Million
Quest acquired Blueprint Genetics (Helsinki, Finland) for $108 million, adding genetic testing capabilities for rare diseases and expanding Quest's international genomics expertise.
Source: en.wikipedia.orgJim Davis Becomes CEO, Succeeding Steve Rusckowski
Jim Davis succeeded Steve Rusckowski as CEO on November 1, 2022, after serving as Executive Vice President of General Diagnostics. Davis brought experience from GE Healthcare, InSightec, and McKinsey & Company. He became Chairman on April 1, 2023.
Source: en.wikipedia.orgAcquisition of Haystack Oncology and NewYork-Presbyterian Outreach
Quest acquired Haystack Oncology, a minimal residual disease testing company, and the outreach laboratory operations of NewYork-Presbyterian Hospital for $275 million, expanding advanced oncology diagnostics and health system partnerships.
Source: en.wikipedia.orgAcquisition of LifeLabs from OMERS for CAD $1.35 Billion
Quest completed the acquisition of LifeLabs from OMERS for approximately CAD $1.35 billion (USD ~$1 billion), adding Canada's leading laboratory diagnostic provider with 6,500+ employees, 8+ million online portal users, and approximately CAD $970 million in annual revenue. LifeLabs continues to operate under its own brand.
Source: en.wikipedia.orgAcquisition of Fresenius Medical Care Spectra Laboratories Assets
Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories and began providing comprehensive dialysis-related laboratory services for Fresenius-operated centers serving approximately 200,000 patients annually in the United States.
Source: en.wikipedia.orgRecord Financial Performance and Raised 2026 Guidance
Quest reported record 2025 results with $11.035 billion in revenue (up 11.8%), operating income of $1.556 billion (up 15.6%), and cash from operations of $1.886 billion (up 41.4%). The company raised 2026 guidance and increased its quarterly dividend 7.5% to $0.86 per share.
Source: en.wikipedia.orgQ1 2026 Results Raise Guidance
Quest Diagnostics reports Q1 2026 revenues of $2.895B, 9.0% organic revenue growth, and raises FY2026 net revenue guidance to $11.78B-$11.90B.
Source: ir.questdiagnostics.comQ2 2026 Results and Second Guidance Raise
Quest reported Q2 2026 revenue of $3.043B (up 10.2%, 10.0% organic) and adjusted diluted EPS of $3.12 (up 19.1%). It raised FY2026 revenue guidance to $11.95B-$12.05B. New York State approved Haystack MRD in the same period.
Source: newsroom.questdiagnostics.comMajor Acquisitions
SmithKline Beecham Clinical Laboratories
1999Quest acquired SBCL to become the clear industry leader in diagnostic testing. SBCL added a national network of regional laboratories, specialty testing operations, STAT laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size.
Unilab Corporation
2003Quest acquired Unilab to significantly expand its West Coast presence, particularly in California. Unilab was a major regional laboratory operator with strong market positions on the West Coast.
AmeriPath and Specialty Laboratories
2007Quest acquired AmeriPath to add anatomic pathology and cancer diagnostic testing capabilities. AmeriPath was a leading provider of anatomic pathology, dermatopathology, and molecular diagnostics.
Solstas Lab Partners Group
2014Quest acquired Solstas to expand its geographic footprint in the Southeastern United States and add hospital outreach laboratory relationships in that region.
Blueprint Genetics
2020Quest acquired Blueprint Genetics (Helsinki, Finland) to add genetic testing capabilities for rare diseases and hereditary conditions, expanding Quest's genomics and precision medicine portfolio.
Haystack Oncology
2023Quest acquired Haystack Oncology, a minimal residual disease (MRD) testing company, to enter the emerging MRD testing market for solid tumors. MRD testing monitors cancer recurrence by detecting circulating tumor DNA.
LifeLabs
2024Quest acquired LifeLabs from OMERS to establish a dominant position in Canadian laboratory services and expand internationally. LifeLabs is Canada's leading lab provider with 6,500+ employees and 8+ million online portal users.
Spectra Laboratories (select assets from Fresenius Medical Care)
2025Quest acquired select clinical testing assets from Fresenius Medical Care's Spectra Laboratories to expand renal-specific testing capabilities for dialysis patients.
Keep researching Quest Diagnostics
Quest Diagnostics Company History FAQ
What are the major historical milestones in the evolution of Quest Diagnostics Incorporated?
Key milestones: Dr. Paul Brown founded Metropolitan Pathology Laboratory in 1967. Corning Glass Works acquired it in 1982, and it was spun off as Quest Diagnostics in 1996. Quest then bought SmithKline Beecham Clinical Laboratories (1999), Unilab (2003), AmeriPath (2007), Haystack Oncology (2023) and LifeLabs (2024).
How did Quest Diagnostics become an independent public company in December 1996?
On December 31, 1996, Corning spun off its diagnostic laboratory subsidiary to shareholders as an independent public company traded on the NYSE under the ticker symbol 'DGX', establishing Quest Diagnostics as a focused pure-play healthcare leader.
How did Quest expand esoteric genetic diagnostics during the Human Genome Project era?
During the 1990s and 2000s, Quest invested heavily in specialized genetic testing, opening its prestigious Nichols Institute esoteric testing facility in San Juan Capistrano, California, pioneering tests for endocrinology, infectious disease viral loads (HIV/Hepatitis C), and oncology biomarkers.
How did the 2020 COVID-19 pandemic demonstrate Quest's national diagnostic infrastructure?
During 2020-2022, Quest served as a critical pillar of the US healthcare response: scaling high-throughput automated PCR testing from scratch, partnering with the CDC and federal government, and performing more than 100 million COVID-19 molecular and antibody tests.
What was the significance of opening the Clifton, New Jersey automated flagship lab in 2021?
In 2021, Quest consolidated several aging regional laboratories into a brand-new 250,000-square-foot flagship automated laboratory in Clifton, New Jersey, one of the largest and most technologically advanced commercial testing facilities in medical history.
How did Quest transition from physician-only ordering to consumer-empowered testing?
In 2018-2019, Quest launched QuestDirect, pioneering consumer-initiated testing that empowers individuals to order certified lab tests directly online, track biomarkers on mobile apps, and take proactive ownership of their preventive health.
How has Quest advanced oncology diagnosis from tissue biopsies to liquid biopsies?
Quest evolved from traditional microscope pathology in 1967 to next-generation genomic sequencing and ultra-sensitive ctDNA liquid biopsies (Haystack Oncology), allowing oncologists to detect minute residual cancer cells through a simple blood draw.
What is Quest Diagnostics' strategic vision for the future of diagnostic information services?
Quest's forward vision focuses on harnessing artificial intelligence for predictive disease screening, accelerating hospital lab partnerships, expanding digital consumer health, and delivering actionable diagnostic insights that improve patient health outcomes worldwide.
When and where was Quest Diagnostics founded?
Quest Diagnostics was founded in 1967 in New York City by Dr. Paul A. Brown, M.D., originally incorporated as Metropolitan Pathology Laboratory, Inc. with a $500 loan from his father-in-law.
What was Dr. Paul Brown’s original innovation in medical testing?
Dr. Brown recognized that hospital labs were inefficient and costly; by setting up an independent pathology lab with automated equipment and couriers to collect blood specimens directly from doctors’ offices, he delivered faster, cheaper diagnostic results.
How did Corning Glass become involved with Quest Diagnostics?
In 1982, Corning Glass Works acquired the company (then known as MetPath) for $140 million, integrating it into its health sciences division and renaming it Corning Clinical Laboratories.
When did Quest Diagnostics spin off and become an independent public company?
On December 31, 1996, Corning spun off Corning Clinical Laboratories to shareholders as an independent public company, which officially rebranded as Quest Diagnostics Incorporated and listed on the NYSE under ticker DGX.
What was the landmark SmithKline Beecham acquisition in 1999?
In 1999, Quest acquired SmithKline Beecham Clinical Laboratories for $1.3 billion, instantly doubling its size to become the largest clinical testing provider in the United States.
What was the Nichols Institute acquisition and why was it vital?
In 1994, the company acquired the Nichols Institute in San Juan Capistrano, California, establishing world-class reference laboratory capabilities in advanced esoteric testing, endocrinology, genetics, and oncology.
How did Quest Diagnostics support the nation during the COVID-19 pandemic?
Quest played a critical national role during the COVID-19 pandemic, rapidly scaling automated PCR molecular testing and serology antibody testing, performing tens of millions of diagnostic tests for patients, healthcare workers, and employers.
When did Jim Davis become CEO of Quest Diagnostics?
In November 2022, James E. (Jim) Davis succeeded longtime CEO Steve Rusckowski as Chairman and Chief Executive Officer, guiding Quest’s post-pandemic growth across consumer health, oncology, and hospital partnerships.
Related Strategic History
Compare founding milestones and corporate evolution
Explore Quest Diagnostics
Core profile pages, founders and related research hubs for this company.